Angiotensin-converting enzyme inhibitor-associated angioedema

Immunol Allergy Clin North Am. 2006 Nov;26(4):725-37. doi: 10.1016/j.iac.2006.08.001.


Angioedema, characterized by swelling of the lips, face, and tongue, occurs in anywhere from 0.1% to 6% of angiotensin-converting enzyme (ACE) inhibitor users. The incidence is more common in black Americans than in white Americans, in women than in men, and in smokers than in nonsmokers. The remitting and relapsing nature of ACE inhibitor-associated angioedema can confound clinical recognition of the adverse event but also provides clues to its causes. Defective degradation of vasoactive peptide substrates of ACE, such as bradykinin or substance P, may contribute via non-ACE pathways to the pathogenesis of ACE inhibitor-associated angioedema.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Angioedema / chemically induced*
  • Angioedema / genetics
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Animals
  • Genetic Predisposition to Disease
  • Humans
  • Pedigree


  • Angiotensin-Converting Enzyme Inhibitors